Étiquette : ptsd

Why Psychiatry Needs 3,4 Methylenedioxymethamphetamine : A Child Psychiatrist’s Perspective, Ben SESSA, 2017

Why Psychiatry Needs 3,4 Methylenedioxymeth-amphetamine : A Child Psychiatrist’s Perspective Ben SESSA Neurotherapeutics, 2017, 14, (3), 741-749. doi:10.1007/s13311-017-0531-1 Abstract Since the late 1980s the psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) has had a well-known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as a therapeutic agent and that in recent years an increasing amount of clinical research has been undertaken to revisit the drug’s medical potential. MDMA has unique pharmacological properties that translate well to its proposed agent to assist trauma-focused psychotherapy. Psychological trauma—especially that which arises early in life from child abuse—underpins many [...]

Lire la suite

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity, Robin L. Carhart-Harris et al., 2015

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity Robin L. Carhart-Harris, Kevin Murphy, Robert Leech, David Erritzoe, Matthew B. Wall, Bart Ferguson, Luke T.J. Williams, Leor Roseman, Stefan Brugger, Ineke De Meer, Mark Tanner, Robin Tyacke, Kim Wolff, Ajun Sethi, Michael A.P. Bloomfield, Tim M. Williams, Mark Bolstridge, Lorna Stewart, Celia Morgan, Rexford D. Newbould, Amanda Feilding, H. Val Curran, and David J. Nutt Biological Psychiatry, 2015, 78, 554-562. http://dx.doi.org/10.1016/j.biopsych.2013.12.015   ABSTRACT BACKGROUND : The compound 3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine releaser that produces an acute euphoria in most individuals. METHODS : [...]

Lire la suite

Psychedelics, David E. Nichols, 2016

Psychedelics David E. Nichols Pharmacological Review, 2016, 68, 264–355 http://dx.doi.org/10.1124/pr.115.011478   Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .266 I. Introduction . . . . . . . . . . . . . . . . . . . . . . . [...]

Lire la suite

Priority Considerations for Medicinal Cannabis-Related Research, Marcel O. Bonn-Miller et al.,

Priority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045   Keywords : medicinal cannabis; medical marijuana   Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]

Lire la suite

Consideration of Ayahuasca for the Treatment of Posttraumatic Stress Disorder, Jessica L. NIELSON, & Julie D. MEGLER, 2012

Consideration of Ayahuasca for the Treatment of Post-traumatic Stress Disorder Jessica L. NIELSON, & Julie D. MEGLER MAPS Bulletin Annual Report, Winter 2012, 29-31.   THERE IS A GROWING AMOUNT OF RESEARCH on the development of PTSD and its various treatments. The fact that many people who su!er from PTSD struggle with the currently approved therapeutic options that are available to them suggests that we need to start exploring alternative strategies to treat this disorder.1 With the large number of veterans returning home from war that may have or will develop PTSD, we must have a diverse framework of therapy and integration in place [...]

Lire la suite

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies, Matthew E. Sloan et al., 2018

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies Matthew E. Sloan, Caroline W. Grant, Joshua L. Gowin, Vijay A. Ramchandani and Bernard Le Foll Acta Pharmacologica Sinica, 2018, 0, 1–9; https://doi.org/10.1038/s41401-018-0081-z   Endocannabinoid signaling is implicated in an array of psychopathologies ranging from anxiety to psychosis and addiction. In recent years, radiotracers targeting the endocannabinoid system have been used in positron emission tomography (PET) studies to determine whether individuals with psychiatric disorders display altered endocannabinoid signaling. We comprehensively reviewed PET studies examining differences in endocannabinoid signaling between individuals with psychiatric illness and healthy controls. Published studies evaluated individuals with five psychiatric [...]

Lire la suite

From experimental psychosis to resolving traumatic pasts – Psychedelic Research in Communist Czechoslovakia, 1954‑1974, Sarah Marks, 2015

From experimental psychosis to resolving traumatic pasts - Psychedelic Research in Communist Czechoslovakia, 1954‑1974 De la psychose expérimentale à la guérison des traumatismes du passé : la recherche psychédélique en Tchécoslovaquie communiste, 1954‑1974 Sarah Marks Cahiers du monde russe, 2015, 56, 1, 53-75. DOI: 10.4000/monderusse.8165   The mid‑twentieth century saw an abundance of new theories of human behaviour and mental disorder, many of which were inspired by new developments in broader scientific fields, from cybernetics and genetics, to pharmaceuticals and new technologies of psychological testing1. There is a developing historical literature on the development of psychiatry in Western Europe and North America, yet we know little [...]

Lire la suite

Psychedelic microdosing benefits and challenges : an empirical codebook, Thomas Anderson et al., 2019

Psychedelic microdosing benefits and challenges : an empirical codebook Thomas Anderson, Rotem Petranker, Adam Christopher, Daniel Rosenbaum, Cory Weissman, Le-Anh Dinh-Williams, Katrina Hui, Emma Hapke Harm Reduction Journal, 2019. Doi : 10.1186/s12954-019-0308-4   Abstract Background : Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. Methods : In the present study, [...]

Lire la suite

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study, Alicia L. Danforth, Charles S. Grob et al., 2018

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults : a randomized, double-blind, placebo-controlled pilot study Alicia L. Danforth, Charles S. Grob, Christopher Struble, Allison A. Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski & Amy Emerson Psychopharmacology, 2018, https://doi.org/10.1007/s00213-018-5010-9   Abstract Rationale : Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted. Objectives : To explore feasibility and safety ofMDMA-assisted psychotherapy for reduction of social fear and avoidance that are common in the autistic population. Methods : Autistic adults with marked to [...]

Lire la suite